Refractory Hodgkin lymphoma: time for targeted therapies?

摘要

With the use of targeted therapies in classical Hodgkin lymphoma (HL), the paradigm of salvage chemotherapy followed by autotransplant may have changed. In this issue of Blood, Herrera et al report positive results using targeted therapy for salvage treatment before autotransplantation.(1)